Emergent BioSolutions (EBS) to Release Earnings on Monday

Emergent BioSolutions (NYSE:EBS) will likely be issuing its quarterly earnings data after the market closes on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $254.67 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Emergent BioSolutions Stock Down 1.3 %

EBS opened at $7.74 on Monday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock has a market cap of $419.44 million, a price-to-earnings ratio of -1.89 and a beta of 1.62. Emergent BioSolutions has a twelve month low of $1.82 and a twelve month high of $15.10. The company’s 50-day moving average price is $9.66 and its two-hundred day moving average price is $9.09.

Wall Street Analysts Forecast Growth

EBS has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Finally, Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.